Evidence map›Paper›PMID 28143772›Full record

ArticleGastroenterology2017

Stearoyl-CoA Desaturase Promotes Liver Fibrosis and Tumor Development in Mice via a Wnt Positive-Signaling Loop by Stabilization of Low-Density Lipoprotein-Receptor-Related Proteins 5 and 6.

Keane K Y Lai, Soo-Mi Kweon, Feng Chi, Edward Hwang, Yasuaki Kabe, Reiichi Higashiyama, Lan Qin, Rui Yan, Raymond P Wu, Keith Lai and 9 more

Abstract read
In one paragraph

Article in Gastroenterology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 116 papers.

0numbers the graph read from it
0cells of the map it votes in
116citing papers in PubMed
7.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

116 citing papers in PubMed, 163 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Targeting Lung Cancer Metabolism: Therapeutic Opportunities and Challenges.Advances in experimental medicine and biology · 2026
    Review
  8. TheAnimals : an open access journal from MDPI · 2025
    Article
  9. Article
  10. Review
  11. H3K36me3-Guided mAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. [Role of metabolic reprogramming-mediated hepatic stellate cell activation in the pathogenesis of hepatic fibrosis].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024
    Review

56 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 7 institutions in 2 countries.

Keane K Y LaiSouthern California Research Center for ALPD and Cirrhosis, Department of Pathology, University of Southern California, Los Angeles, California.
Soo-Mi KweonSouthern California Research Center for ALPD and Cirrhosis, Department of Pathology, University of Southern California, Los Angeles, California.
Feng ChiSouthern California Research Center for ALPD and Cirrhosis, Department of Pathology, University of Southern California, Los Angeles, California.
Edward HwangSouthern California Research Center for ALPD and Cirrhosis, Department of Pathology, University of Southern California, Los Angeles, California.
Yasuaki KabeDepartment of Biochemistry, Keio University School of Medicine, Tokyo, Japan.
Reiichi HigashiyamaSouthern California Research Center for ALPD and Cirrhosis, Department of Pathology, University of Southern California, Los Angeles, California.
Lan QinSouthern California Research Center for ALPD and Cirrhosis, Department of Pathology, University of Southern California, Los Angeles, California.
Rui YanSouthern California Research Center for ALPD and Cirrhosis, Department of Pathology, University of Southern California, Los Angeles, California.
Raymond P WuSouthern California Research Center for ALPD and Cirrhosis, Department of Pathology, University of Southern California, Los Angeles, California.
Keith LaiDepartment of Anatomic Pathology, Cleveland Clinic, Cleveland, Ohio.
Naoaki FujiiDepartment of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, Tennessee.
Samuel FrenchSouthern California Research Center for ALPD and Cirrhosis, Department of Pathology, University of Southern California, Los Angeles, California; Harbor-University of California Los Angeles Medical Center, Torrance, California.
Jun XuSouthern California Research Center for ALPD and Cirrhosis, Department of Pathology, University of Southern California, Los Angeles, California.
Jian-Ying WangDepartments of Surgery and Pathology, University of Maryland School of Medicine, Baltimore, Maryland.
Ramachandran MuraliSouthern California Research Center for ALPD and Cirrhosis, Department of Pathology, University of Southern California, Los Angeles, California; Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California.
Lopa MishraDepartment of Surgery and Cancer Center, George Washington University, Washington, District of Columbia.
Ju-Seog LeeDepartment of Systems Biology, University of Texas MD Anderson Cancer Center, Houston, Texas.
James M NtambiDepartments of Biochemistry and Nutritional Sciences, University of Wisconsin-Madison, Madison, Wisconsin.
Hidekazu TsukamotoSouthern California Research Center for ALPD and Cirrhosis, Department of Pathology, University of Southern California, Los Angeles, California; Department of Veterans Affairs, Greater Los Angeles Healthcare System, Los Angeles, California. Electronic address: htsukamo@usc.edu.
University of Southern California · USGeorge Washington University · USKeio University · JPSt. Jude Children's Research Hospital · USThe University of Texas MD Anderson Cancer Center · USUniversity of Maryland, Baltimore · USUniversity of Wisconsin–Madison · US

Funding

The Southernearch Center for ALPD and CirrhosisP50AA011999 · NIAAA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ANNA S. GUKOVSKAYA · 1999 to 2026
$45.8M
USC RESEARCH CENTER FOR LIVER DISEASES: PILOT PROGRAMSP30DK048522 · NIDDK · UNIVERSITY OF SOUTHERN CALIFORNIA · PI DELEVE, LAURIE D · 1995 to 2020
$21.8M
NON-PARENCHYMAL LIVER CELL CORER24AA012885 · NIAAA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TSUKAMOTO, HIDEKAZU · 2001 to 2025
$8.1M
Surgical Studies of Gut PermeabilityR01DK068491 · NIDDK · UNIVERSITY OF MARYLAND BALTIMORE · PI Jian-Ying Wang · 2004 to 2026
$7.0M
Mucosal Repair in Gut Surgical DisordersR01DK061972 · NIDDK · UNIVERSITY OF MARYLAND BALTIMORE · PI WANG, JIAN-YING · 2002 to 2023
$6.7M
Role of Beta Spectrin and Smad in Alcohol-Induced Liver and GI Cell ProliferationR01AA023146 · NIAAA · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Lopa Mishra · 2013 to 2026
$4.6M
Epigenetic Regulation of Alcoholic Liver FibrosisU01AA018663 · NIAAA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI KISSELEVA, TATIANA, MANN, DEREK · 2010 to 2019
$3.7M
Role of Stearoyl-CoA Desaturase in MetabolismR01DK062388 · NIDDK · UNIVERSITY OF WISCONSIN-MADISON · PI NTAMBI, JAMES M. · 2002 to 2010
$2.6M
Molecular Mechanisms and Translational studies in Colon CancerI01BX003732 · VA · U.S. DEPT/VETS AFFAIRS MEDICAL CENTER · PI MISHRA, LOPA · 2017 to 2019
–
Molecular Mechanisms of Stellate Cell Activation in Liver FibrosisI01BX001991 · VA · VA GREATER LOS ANGELES HEALTHCARE SYSTEM · PI HIDEKAZU TSUKAMOTO · 2014 to 2026
–
REGULATION OF INTESTINAL EPITHELIAL RESTITUTIONI01BX000332 · VA · BALTIMORE VA MEDICAL CENTER · PI Jian-Ying Wang · 2009 to 2026
–
BLRD VA I01 BX000332BLRD VA I01 BX001991BLRD VA I01 BX003732NIAAA NIH HHS P50 AA011999NIAAA NIH HHS R01 AA023146NIAAA NIH HHS R24 AA012885NIAAA NIH HHS U01 AA018663NIDDK NIH HHS P30 DK048522NIDDK NIH HHS R01 DK061972NIDDK NIH HHS R01 DK062388NIDDK NIH HHS R01 DK068491
6 · The paper itself

Abstract

BACKGROUND &

aimsStearoyl-CoA desaturase (SCD) synthesizes monounsaturated fatty acids (MUFAs) and has been associated with the development of metabolic syndrome, tumorigenesis, and stem cell characteristics. We investigated whether and how SCD promotes liver fibrosis and tumor development in mice.

methodsRodent primary hepatic stellate cells (HSCs), mouse liver tumor-initiating stem cell-like cells (TICs), and human hepatocellular carcinoma (HCC) cell lines were exposed to Wnt signaling inhibitors and changes in gene expression patterns were analyzed. We assessed the functions of SCD by pharmacologic and conditional genetic manipulation in mice with hepatotoxic or cholestatic induction of liver fibrosis, orthotopic transplants of TICs, or liver tumors induced by administration of diethyl nitrosamine. We performed bioinformatic analyses of SCD expression in HCC vs nontumor liver samples collected from patients, and correlated levels with HCC stage and patient mortality. We performed nano-bead pull-down assays, liquid chromatography-mass spectrometry, computational modeling, and ribonucleoprotein immunoprecipitation analyses to identify MUFA-interacting proteins. We examined the effects of SCD inhibition on Wnt signaling, including the expression and stability of low-density lipoprotein-receptor-related proteins 5 and 6 (LRP5 and LRP6), by immunoblot and quantitative polymerase chain reaction analyses.

resultsSCD was overexpressed in activated HSC and HCC cells from patients; levels of SCD messenger RNA (mRNA) correlated with HCC stage and patient survival time. In rodent HSCs and TICs, the Wnt effector β-catenin increased sterol regulatory element binding protein 1-dependent transcription of Scd, and β-catenin in return was stabilized by MUFAs generated by SCD. This loop required MUFA inhibition of binding of Ras-related nuclear protein 1 (Ran1) to transportin 1 and reduced nuclear import of elav-like protein 1 (HuR), increasing cytosolic levels of HuR and HuR-mediated stabilization of mRNAs encoding LRP5 and LRP6. Genetic disruption of Scd and pharmacologic inhibitors of SCD reduced HSC activation and TIC self-renewal and attenuated liver fibrosis and tumorigenesis in mice. Conditional disruption of Scd2 in activated HSCs prevented growth of tumors from TICs and reduced the formation of diethyl nitrosamine-induced liver tumors in mice.

conclusionsIn rodent HSCs and TICs, we found SCD expression to be regulated by Wnt-β-catenin signaling, and MUFAs produced by SCD provided a forward loop to amplify Wnt signaling via stabilization of Lrp5 and Lrp6 mRNAs, contributing to liver fibrosis and tumor growth. SCD expressed by HSCs promoted liver tumor development in mice. Components of the identified loop linking HSCs and TICs might be therapeutic targets for liver fibrosis and tumors.

Indexed as

Animalsbeta Cateninbeta KaryopherinsCarcinoma, HepatocellularCase-Control StudiesCell Line, TumorCholestasisDiethylnitrosamineELAV-Like Protein 1Fatty Acids, MonounsaturatedHepatic Stellate CellsHumansLiver CirrhosisLiver NeoplasmsLow Density Lipoprotein Receptor-Related Protein-5Low Density Lipoprotein Receptor-Related Protein-6beta Cateninbeta KaryopherinsDiethylnitrosamineElavl1 protein, mouseELAV-Like Protein 1Fatty Acids, MonounsaturatedLow Density Lipoprotein Receptor-Related Protein-5Low Density Lipoprotein Receptor-Related Protein-6ran GTP-Binding ProteinRNA, MessengerScd2 protein, mouseStearoyl-CoA DesaturaseSterol Regulatory Element Binding Protein 1Tnpo1 protein, mouseCancer Stem CellsHCCHepatocarcinogenesisHuR

Identifiers

PMID28143772
PMCPMC5406249
OpenAlexW2582893389

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.